“Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one’s entire investment thanks to their vulnerability to catalytic events,” acknowledges the author of today’s article before proceeding to identify nine biotech stocks with key catalysts in the final months of 2020. For these nine stocks and their respective fourth-quarter catalysts and price targets, CLICK HERE.
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…
“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview…
Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes…
A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these…
The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the…
There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a…
With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company…
“These companies are all making important strides in next-gen solutions for COVID-19, cancer and other sectors. But remember, they’re small companies in a risky space, nibble on them and be patient,” advise the authors of today’s article in regards to the seven “A-rated” aggressive biotech stocks they highlight. For these seven biotech stocks – and whether they could be “Master…
The portfolio manager of one biotech-focused hedge fund recently invested a total of $60 million in three biotech stocks – and given his strong performance record and ability to beat the wider biotech sector with his picks, it may be worth taking a look at his selections. For the three biotech stocks in question, CLICK HERE.